ROP is among the leading German patent litigation practices and continued along its path following successful rejuvenation in recent years. The firm was active in two major NPE suits for LG. Young partners like Hilge used this to gain market profile. Rospatt and Musmann’s pharmaceuticals team put in its usual strong performance in many proceedings, incl. for Bayer and Biogen. ROP also saw an improvement in teamwork between its partners, like Hoyng ROKH Monegier has long enjoyed. Since the Brexit referendum, ROP can relax again with regard to the UPC, as it has been coping without a London office despite its strong pharmaceuticals specialty. Solidifying its good ties to British firms Bristows and Powell Gilbert would be a good move nevertheless, as German firms are vying for the attention of both.
Litigation, strong international contacts.
Max von Rospatt, Thomas Musmann, Dr. Henrik Timmann, Stephan von Petersdorff-Campen, Hetti Hilge.
7 partners, 5 associates
Predominantly litigation and advice in IP and adjacent practice areas, such as pharma advertising law and antitrust. Clear focus on patent infringement proceedings. Broad spectrum of expertise, esp. in the pharmaceuticals, medical technology, telecoms and auto sectors. Trademarks and unfair competition.
Samsung against Fipa; LG against Unwired Planet and Saint Lawrence (SLC; all regarding mobile communications); Biogen regarding Tecfidera; Rhodia concerning catalysts; Merck Sharp Dome regarding cancer immunotherapy; Unilin concerning laminates; Bayer regarding PEGylated Factor III; Lucas Industries concerning auto technology; Osram regarding lighting technology.